EyePoint Schedule 13G: Paradigm reports 5.1% stake

EyePoint, Inc. Schedule 13G discloses that Paradigm-related reporting persons hold disclosed stakes in EyePoint's common stock as of the close of business on 02/17/2026.

Rhea-AI Filing Summary

EyePoint, Inc. Schedule 13G discloses that Paradigm-related reporting persons hold disclosed stakes in EyePoint's common stock as of the close of business on 02/17/2026.

The filing shows Paradigm BioCapital Advisors (and related entities) with 4,192,261 shares ( 5.1%) and Paradigm BioCapital International Fund Ltd. with 3,694,542 shares ( 4.5%). The ownership percentages are calculated using 82,787,220 shares outstanding as of 10/30/2025.

Insights

Corporate Governance Analyst

Paradigm reports passive beneficial ownership around mid-single-digit percentages.

The statement lists beneficial ownership amounts for the Adviser, Adviser GP, the managing member, and the Fund with 4,192,261 shares (5.1%) and 3,694,542 shares (4.5%) tied to specific reporting persons as of 02/17/2026. The percentages reference 82,787,220 shares outstanding as of 10/30/2025.

Filing language describes the Fund and managed accounts as the direct owners and the Adviser and Adviser GP as investment manager/general partner; each reporting person disclaims ownership beyond shares directly owned. Subsequent filings would show any change in holdings.

Equity Capital Markets Specialist

Holdings are below typical control thresholds but represent visible institutional positions.

The disclosure attributes sole voting and dispositive power for the listed share counts to the reporting persons (e.g., 4,192,261 shares for Paradigm BioCapital Advisors). The cover page cites sole voting and dispositive power values explicitly.

These positions are presented as beneficial ownership only; the filing does not state any planned transactions or changes to capital structure. Any market impact depends on future, separately disclosed actions by the holders.

FAQ

What stake does Paradigm BioCapital report in EyePoint (EYPT)?

Paradigm BioCapital Advisors reports beneficial ownership of 4,192,261 shares (5.1%). The filing shows this figure as sole voting and dispositive power and cites 82,787,220 shares outstanding as of 10/30/2025 used to calculate the percentage.

How many shares does Paradigm BioCapital International Fund hold in EYPT?

Paradigm BioCapital International Fund Ltd. holds 3,694,542 shares (4.5%). The filing lists this amount with sole voting and dispositive power and references the outstanding share count of 82,787,220 as of 10/30/2025.

What date do the ownership figures in the Schedule 13G reflect?

The ownership amounts are given as of the close of business on 02/17/2026. The filing also states percentages based on 82,787,220 shares outstanding as of 10/30/2025, per the issuer's Form 10-Q.

Do the reporting persons claim full beneficial ownership personally?

No; each reporting person disclaims ownership beyond the shares directly beneficially owned by that person. The Adviser, Adviser GP, and managing member describe their relationship to the Fund and managed accounts and disclaim ownership beyond direct holdings.

Who has voting and dispositive power over the disclosed shares?

The cover page attributes sole voting and sole dispositive power to the reporting persons for the stated share counts. For example, Paradigm BioCapital Advisors shows sole voting and dispositive power for 4,192,261 shares on the cover page.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 04:00 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

EyePoint, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

30233G209

(CUSIP Number)

02/17/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 30233G209

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,192,261.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,192,261.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,192,261.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 30233G209

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,192,261.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,192,261.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,192,261.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP No. 30233G209

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,192,261.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,192,261.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,192,261.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 30233G209

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,694,542.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,694,542.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,694,542.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.5 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: EyePoint, Inc.
(b)	Address of issuer's principal executive offices: 480 Pleasant Street Watertown, MA, 02472
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 767 Third Avenue, 17th Floor, New York, NY 10017.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 30233G209
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on February 17, 2026.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 82,787,220 shares of Common Stock outstanding as of October 30, 2025, as reported by the Issuer in its Form 10-Q filed with the SEC on November 6, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	02/24/2026

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	02/24/2026

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	02/24/2026

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	02/24/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement.